Results 181 to 190 of about 6,343,118 (411)

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

open access: yesMolecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton   +17 more
wiley   +1 more source

Eight-month of physical training in warm water improves physical and mental health in women with fibromyalgia: a randomized controlled trial [PDF]

open access: yes, 2008
OBJECTIVE: To evaluate the feasibility of 8 months of supervised exercise therapy in warm water and its effects on the impact of fibromyalgia on physical and mental health and physical fitness in affected women.
Gusi, Narcis   +5 more
core  

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

open access: yesMolecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop   +10 more
wiley   +1 more source

The acute effects of two different self-myofascial release products on the calf muscle pump and plantar flexion ankle range of motion [PDF]

open access: yes, 2015
textBackground: Massage can promote healing and recovery following exercise. (Carefelli et al. 1992). Barnes (1990) proposed that myofascial release helps to break up fibrotic fascial adhesions that may restrict joint range of motion (ROM).
Fleisher, Timothy Michael
core  

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

open access: yesMolecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed   +8 more
wiley   +1 more source

Neutral Protamine Hagedorn (NPH) insulin attenuates memory impairments in diabetic rats

open access: yesDiabetology & Metabolic Syndrome
Cognitive decline is a significant complication of type 1 diabetes (T1D) that substantially affects patients' quality of life. Although previous studies suggest that Neutral Protamine Hagedorn (NPH) insulin may mitigate certain effects of streptozotocin ...
Marcelo T. Andrade   +12 more
doaj   +1 more source

Exercise as therapy for Parkinson's?

open access: yesAging, 2018
Crowley, Erin K.   +2 more
openaire   +3 more sources

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

open access: yesMolecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski   +19 more
wiley   +1 more source

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

open access: yesMolecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy